July 3, 2025

Roswell Park Comprehensive Cancer Center

Study Featured at ASCO 2025 Highlights Potential New Treatment for Aggressive Form of Acute Myeloid Leukemia | Newswise

Study Featured at ASCO 2025 Highlights Potential New Treatment for Aggressive Form of Acute Myeloid Leukemia | Newswise

David Bale07 mins

Highlights Ziftomenib produces deep, durable responses in patients with NPM1 mutations Potential new treatment option for those with relapsed/refractory disease Investigational drug granted Breakthrough Therapy designation by FDA last year Newswise — BUFFALO, N.Y. and CHICAGO — An international clinical trial co-led by Roswell Park Comprehensive Cancer Center has demonstrated that the investigational drug ziftomenib…

Read More
Study Featured at ASCO 2025 Highlights Potential New Treatment for Aggressive Form of Acute Myeloid Leukemia | Newswise

Roswell Park Expert to Share Promising Results on New Immunotherapy Approach in Non-Small Cell Lung Cancer | Newswise

David Bale06 mins

Highlights Investigational drug shows activity in anti-PD1-resistant lung cancer Targeting adenosine may enhance effectiveness of immunotherapy Favorable safety/tolerability profile observed Newswise — BUFFALO, N.Y. and CHICAGO — Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system’s ability to…

Read More
Study Featured at ASCO 2025 Highlights Potential New Treatment for Aggressive Form of Acute Myeloid Leukemia | Newswise

Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025 | Newswise

David Bale031 mins

Highlights Dr. Jain reports results of phase 1 study for non-small cell lung cancer Poster presentations highlight latest findings across a range of disease sites Annual meeting takes place April 25-30 in Chicago Newswise — BUFFALO, N.Y. and CHICAGO — Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues from…

Read More
Study Featured at ASCO 2025 Highlights Potential New Treatment for Aggressive Form of Acute Myeloid Leukemia | Newswise

Roswell Park-Led Research Reveals a Hidden Vulnerability of Lung Cancer | Newswise

David Bale05 mins

Highlights Findings of preclinical study point the way to promising combination therapy Protein agrin seen as potential biomarker for determining treatment response Study published in Advanced Science; further findings to be presented at AACR BUFFALO, N.Y. — Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin,…

Read More
Roswell Park-Led Team Proposes CDK2 Enzyme as New Target for Cancer Therapy | Newswise

Roswell Park-Led Team Proposes CDK2 Enzyme as New Target for Cancer Therapy | Newswise

David Bale06 mins

Researchers hope targeting CDK2 can overcome resistance to CDK4/6 inhibitors Implications for treatment of breast, pancreatic, other cancers Findings published in Nature Communications BUFFALO, N.Y. — An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including a class…

Read More
Roswell Park-Led Team Proposes CDK2 Enzyme as New Target for Cancer Therapy | Newswise

Tandem 2025: Roswell Park Team Creates Predictive Model to Inform Care of Lymphoma Patients | Newswise

David Bale010 mins

Invited talk highlights link between patients’ physical function, CAR T outcomes Holtan to be honored for contributions to combating graft-vs.-host disease Other studies: Prospect for CAR T in breast cancer, ways to improve outcomes BUFFALO, N.Y. — Discoveries made by experts from Roswell Park Comprehensive Cancer Center will be featured at an international conference focusing…

Read More
Roswell Park-Led Team Proposes CDK2 Enzyme as New Target for Cancer Therapy | Newswise

Changes in Microbiome Predict Risk for Sexually Transmitted Infections | Newswise

David Bale09 mins

Specific changes in the cervicovaginal microbiome set the stage for chlamydia Findings in women of color, disproportionately affected by infections but understudied Team reveals previously unknown subtype of BV, bacterial vaginosis January 15, 2025—(BRONX, NY and BUFFALO, NY)—Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial…

Read More
Study Featured at ASCO 2025 Highlights Potential New Treatment for Aggressive Form of Acute Myeloid Leukemia | Newswise

Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer | Newswise

David Bale07 mins

  One of the deadliest types of breast cancer, TNBC has a high recurrence rate Study shows IMPDH2 inhibitors reduce growth of chemo-resistant tumors Findings published in Nature’s Scientific Reports BUFFALO, N.Y. — Triple-negative breast cancer, or TNBC, presents numerous treatment challenges. Compared with other forms of breast cancer, it’s more likely to have spread…

Read More
Roswell Park Team Discovers New Treatment Target f | Newswise

Roswell Park Team Discovers New Treatment Target f | Newswise

David Bale08 mins

Findings from new preclinical study reported in Oncogene Work helps explain why advanced prostate tumors may resist current treatments HSP60 inhibition emerges as promising treatment strategy BUFFALO, N.Y. — A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare…

Read More